文献速递生殖医学

来曲唑用于冻融单胚胎移植周期的妊娠与新生儿结局

Pregnancy and neonatal outcomes following letrozole use in frozen-thawed single embryo transfer cycles.
PubMed 文献 · Hum Reprod · 2017-01-01

基于日本2012至2013年全国ART登记数据的回顾性队列研究,纳入110722个单胚胎冻融移植周期,分为来曲唑组2409个、自然周期组41470个和激素替代周期组66843个。来曲唑组的临床妊娠率、伴胎心临床妊娠率和活产率显著高于自然周期和激素替代周期,流产率显著低于两者;新生儿结局在三组间大多相似。

要点

  • 来曲唑组临床妊娠、伴胎心临床妊娠和活产率显著高于自然周期及激素替代周期。
  • 来曲唑组流产率显著低于自然周期和激素替代周期。
  • 三组新生儿结局大多相似。

核心结论

  • 来曲唑的使用与单胚胎冻融移植周期中较高的临床妊娠率、伴胎心临床妊娠率和活产率显著相关,并与较低的流产率相关。
  • 作者认为来曲唑可能改善单胚胎冻融移植患者的临床妊娠、伴胎心临床妊娠和活产,并降低流产风险。

研究设计与样本

  • 回顾性队列研究,使用日本全国ART登记数据,时间段为2012年至2013年。
  • 共纳入110722个单胚胎冻融移植周期:来曲唑组n=2409,自然周期组n=41470,激素替代周期组n=66843。
  • 采用广义估计方程计算调整比值比和相对危险度(RR),并校正诊所内相关性。

主要发现

  • 来曲唑组临床妊娠率、伴胎心临床妊娠率和活产率显著高于自然周期组和激素替代周期组,流产率显著低于两组。
  • 在囊胚期移植中,来曲唑组对比自然周期组伴胎心临床妊娠的调整RR为1.48(95%CI:1.41-1.55),对比激素替代周期组的调整RR为1.62(95%CI:1.54-1.70)。
  • 在囊胚期移植中,来曲唑组对比自然周期组流产的调整RR为0.91(95%CI:0.88-0.93),对比激素替代周期组的调整RR为0.84(95%CI:0.82-0.87)。
  • 新生儿结局在来曲唑组、自然周期组和激素替代周期组间大多相似。

临床怎么用

  • 作者认为,来曲唑的使用可能改善单胚胎冻融移植患者的临床妊娠、伴胎心临床妊娠和活产,并降低流产风险。

局限性

  • 本研究的重要局限性包括缺乏选择特定冻融移植方法原因的信息。
  • 缺乏产次信息。
  • 缺乏既往ART失败次数信息。
  • 缺乏胚胎质量信息。
  • 缺乏来曲唑摄入剂量和 duration 的信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are pregnancy and neonatal outcomes following letrozole use comparable with natural and HRT cycles in patients undergoing single frozen-thawed embryo transfer (FET)? SUMMARY ANSWER: Letrozole use was significantly associated with higher rates of clinical pregnancy, clinical pregnancy with fetal heart beat and live birth, and with a lower rate of miscarriage, compared with natural and HRT cycles. WHAT IS KNOWN ALREADY: Letrozole is the most commonly used aromatase inhibitor for mild ovarian stimulation in ART. However, the effect of letrozole on pregnancy and neonatal outcomes in FET are not well known. STUDY DESIGN SIZE, DURATION: A retrospective cohort study was conducted using data from the Japanese national ART registry between 2012 and 2013. PARTICIPANTS/MATERIALS SETTING METHODS: A total of 110 722 single FET cycles with letrozole (n = 2409), natural (n = 41 470) or HRT cycles (n = 66 843) were included. The main outcomes were the rates of clinical pregnancy, clinical pregnancy with fetal heart beat, miscarriage and live birth. Adjusted odds ratios and relative risks (RRs) were calculated using a generalized estimating equation adjusting for correlations within clinics. MAIN RESULTS AND THE ROLE OF CHANCE: The rates of clinical pregnancy, clinical pregnancy with fetal heart beat, and live birth were significantly higher, while the rate of miscarriage was significantly lower in the letrozole group compared with the natural and HRT groups. In blastocyst stage transfers, the adjusted RRs for clinical pregnancy with fetal heart beat of letrozole compared with natural and HRT cycles were 1.48 (95% CI: 1.41-1.55) and 1.62 (95% CI: 1.54-1.70), respectively. Similarly, the adjusted RRs of letrozole for miscarriage compared with natural and HRT cycles were 0.91 (95% CI: 0.88-0.93) and 0.84 (95% CI: 0.82-0.87), respectively. Neonatal outcomes were mostly similar in letrozole, natural and HRT cycles. LIMITATIONS REASONS FOR CAUTION: Important limitations of this study included the lack of information concerning the reasons for selecting the specific FET method, parity, the number of previous ART failures, embryo quality and the dose and duration of letrozole intake. WIDER IMPLICATIONS OF THE FINDINGS: These results suggest that letrozole use may improve clinical pregnancy, clinical pregnancy with fetal heart beat, and live births and reduce the risk of miscarriage in patients undergoing single FET cycles. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used for this study. There are no conflicts of interest. TRIAL REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Tatsumi T, Jwa SC, Kuwahara A, et al. Pregnancy and neonatal outcomes following letrozole use in frozen-thawed single embryo transfer cycles. Hum Reprod. 2017. PMID: 28398491. doi:10.1093/humrep/dex066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。